Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Instrumental orchestrates $20m
Stanford-StartX Fund has backed the electronics manufacturing management software developer, with the proceeds going to product development.
Bright Peak ascends to $35m series A
Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.
Enthera enters $32.8m series A round
Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.
MBX Biosciences extrapolates $34.6m
IU Philanthropic Venture Fund returned for a series A round expected to help MBX identify clinical-stage peptides for rare endocrine genetic diseases.
Vesigen spawns with $28.5m series A
Vesigen has attracted Leaps by Bayer to commercialise drug delivery technology invented by Quan Lu at Harvard School of Public Health.
T3 Pharma treats itself to more funding
Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.
Solugen soldiers on to win $30.2m
MIT-founded biochemical water treatment company Solugen has increased its funding total to at least $48.7m.
Tranquis races out of the traps with $30m
Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.

Other News

VarmX arms itself with $36.2m series B
Lundbeckfonden Ventures took a board seat at Leiden spinout VarmX as part of a round that will fund development of a treatment for spontaneous bleeding.
Corporates help energise Natron's $35m series D
Sodium-ion battery producer Natron, a Stanford spinout, has picked up corporates ABB and Chevron in a round bringing its lifetime funding to more than $70m.
Cutiss replenishes series B funding
University of Zurich-founded skin graft therapy developer Cutiss increased its funding total to $29.3m with a round featuring Wyss Foundation.
Simcha shakes down $25m
Wuxi AppTec and Pfizer have both contributed as the Yale University-founded cancer drug developer prepares for clinical testing next year.
Everbright tracks down $21.2m
Chinese Academy of Sciences-backed laser-diode chip foundry Everbright Photonics has now raised $63.3m since it was founded in 2012.
Ona amasses $33.9m series A
Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg